UCB Deal History & Licensing Activity
UCB is a large pharma headquartered in Belgium. Over the past three years, UCB has been involved in 6 licensing and acquisition transactions, with a primary focus on Cell Therapy (10 deals).
Deals (12mo)
5
Active Trials
12
Top Modality
Cell Therapy
Focus Area
Mega Deals
UCB Recent Deal Activity
Licensing, acquisition, and partnership transactions involving UCB in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| early-stage seizure cell therapy | Neurona | Cell Therapy | Preclinical | acquisition | Apr 2026 |
| Cell therapy for epilepsy | Neurona Therapeutics | Cell Therapy | Phase 1 | acquisition | Apr 2026 |
| cell therapy for epilepsy | Neurona Therapeutic | Cell Therapy | Unknown | acquisition | Apr 2026 |
UCB Pipeline Focus
Therapeutic areas and modalities where UCB is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
UCB Strategic Signals
Key indicators of UCB's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
See How Your Asset Matches UCB's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Mega Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Dermatology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for dermatology
Cell Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for cell therapy deals
Mab Benchmarks
Upfront, milestone, and royalty benchmarks for mab deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About UCB Licensing & Deal Activity
UCB is a large pharma company based in Belgium that has been actively engaged in licensing transactions across the biopharma landscape. With 6 deals over the past three years, UCB ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for UCB include Mega Deals (8 deals and trials), Neurology (2 deals and trials), and Dermatology (1 deal and trial). In terms of modality, UCB has shown particular interest in cell therapy, mab.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for UCB and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against UCB's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.